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ABSTRACT
Data-driven AI promises support for pathologists to discover
sparse tumor patterns in high-resolution histological images.
However, three limitations prevent AI from being adopted into
clinical practice: (i) a lack of comprehensiveness where most
AI algorithms only rely on single criteria/examination; (ii) a
lack of explainability where AI models work as ‘black-boxes’
with little transparency; (iii) a lack of integrability where it
is unclear how AI can become part of pathologists’ existing
workflow. To address these limitations, we propose CrossPath:
a brain tumor grading tool that supports top-down, cross data
type, multi-criterion histological analysis, where pathologists
can shepherd mixed AI models. CrossPath first uses AI to
discover multiple histological criteria with H and E and Ki-67
slides based on WHO guidelines. Second, CrossPath demon-
strates AI findings with multi-level explainable supportive
evidence. Finally, CrossPath provides a top-down shepherding
workflow to help pathologists derive an evidence-based, pre-
cise grading result. To validate CrossPath, we conducted a user
study with pathologists in a local medical center. The result
shows that CrossPath achieves a high level of comprehensive-
ness, explainability, and integrability while reducing about
one-third time consumption compared to using a traditional
optical microscope.
Author Keywords
Digital histology; Medical AI; Human-AI collaboration;
Meningioma
CCS Concepts
•Human-centered computing → Empirical studies in in-
teraction design; •Applied computing→ Life and medical
sciences; •Computing methodologies→ Machine learning;
INTRODUCTION
One critical step in cancer diagnosis and treatment is patholo-
gists’ analysis of histological images obtained from a patient’s
tissue sections to identify evidence of tumor cells and deter-
mine the grade (e.g., benign vs. malignant) based on medical
guidelines.
Such an analysis is often challenging for pathologists, due to
the sheer amount of effort it requires to identify sparse patterns
of tumor cells given the ultra-high resolution of multiple histo-
logical images in a single patient’s case. Further, the process
suffers from subjectivity due to the intra- and inter-observer
variations, e.g., different interpretations of the grading guide-
lines, and different ways of sampling and examining the slides
to ‘implement’ a given guideline.
To overcome these challenges, digital histology, enabled by ad-
vanced scanning techniques, promises to transform traditional
microscopic analysis to digital visualization automatable by
data-driven artificial intelligence (AI) [18]. However, there
remain three limitations of existing AI-aided histological anal-
ysis that prevent its adoption in clinical practice:
• A lack of comprehensiveness: most AI models tend to focus
on one specific criterion inferred from one specific type of
histological data [5, 12, 19, 24, 28, 32, 35, 47] while in
practice pathologists almost always rely on multiple criteria
by examinations across multiple types of data;
• A lack of explainability: most AI models function as ‘black
boxes’ and provide little justifications for the generated
analysis—such a lack of transparency creates a barrier that
prevents AI from being accepted by pathologists;
• A lack of integrability: most AI models abstract histological
analysis as a computational problem, thus it remains unclear
how to integrate such models into pathologists’ existing
workflow and practices;
To address these limitations, we develop CrossPath—a brain
tumor grading tool for pathologists to perform top-down, cross
data type, multi-criterion histological analysis by shepherding
mixed AI models. Currently, we focus on the grading of
meningioma—the most common primary type of brain tumor—
as a point of departure for exploring the design of CrossPath.
The goal is to aid pathologists to grade meningioma with the
aid of AI, which assumes that tumor areas have already been
identified on a slide.
Figure 1 shows an overview of CrossPath’s interface. A typical
workflow follows a top-down path, starting with a pathologist
first seeing the top-level suggested grading (Figure 1e) where
an arrow (Figure 1g) highlights the main contributing criterion
that leads to the suggested grading. The analysis of each
criterion is produced by an AI model that examines a specific
type of histological data (i.e., H&E, Ki-67) based on the World
Health Organization (WHO) guideline. The pathologist can
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Figure 1. User interface of CrossPath: (a) WSI viewer with continuous magnification, the yellow box corresponds to the area of one high power field
in the optical microscope, and the blue box is related to the selected evidence in the evidence list; (b) a user can verify each of the sampled evidence by
clicking on ‘approve’, ‘decline’ or ‘declare uncertain’ button; (c) a heatmap can be enlarged to provide a global distribution of each criterion; (d) a list
of sampled evidence generated by AI, the user can click on each piece of evidence to register each patch into the WSI on the left; (e) auto-generated
suggested grading according to the WHO guideline where each criterion is examined by an AI model (f): both the suggested grading and the findings
on individual criterion would be updated as the user override the AI’s results; (g) an arrow highlights the main contributing criterion to the current
grading result; (h) the user can also shepherd the mixed AI models by overriding each histological feature manually.
further select and drill down to a specific criterion, which
retrieves a set of evidence (Figure 1d) to explain why AI arrives
at its result. For example, for the criterion of mitotic count
(Figure 1f), the pathologist can see patches of evidence (Figure
1d) sampled in the largest aggregation of mitosis. Moreover,
the pathologist can open a heatmap (Figure 1c) overlaying the
whole slide image (WSI) to overview the density distribution
of positive mitotic cells recognized by the AI. Selecting a
patch directs the pathologists’ attention to a high power field
(HPF, Figure 1a, yellow box) of the mitosis on the original
WSI, where they can further examine the low-level histological
features and approve or decline AI’s analysis with one click
(Figure 1b), which in turn will update AI’s results on individual
criterion and, if necessary, the overall suggested grading as
well based on WHO guidelines.
To validate CrossPath, a technical evaluation shows that the
validation performance of AI models achieves an area under
curve (AUC) of 0.842, 0.989, 0.923, and 0.834/0.673 in identi-
fying the mitotic nucleus, necrosis, prominent nucleolus, and
meningothelial/fibrous tissues separately. Moreover, Cross-
Path achieves an averaged error rate of 12.3% and 13.7% in
nuclei counting (hypercellularity) and Ki-67 index calcula-
tion. A user study with seven pathologists shows that, with
less than an hour of learning, pathologists were able to use
CrossPath to make accurate grading decisions, with about one
third reduction in time consumption compared to examining
with the optical microscope. Pathologists’ qualitative feedback
indicates that CrossPath obtains a high level of comprehensive-
ness, explainability, and integrability; meanwhile, the main
challenge is that the current system does not support users to
adjust the prediction threshold via the interface, and hence
resulting in an amount of false-positive evidences that might
influence the suggested result. Another challenge is that par-
ticipants were not used to digital WSI examination since the
size of cells varies from computer monitors because of the
extra digital zoom in the interface.
Contributions
This paper makes a tool contribution to AI-aided pathology,
addressing the three key issues of comprehensiveness, explain-
ability, and integrability.
• CrossPath addresses comprehensiveness by incorporating
multiple WHO-guided criteria across different data types;
• CrossPath addresses explainability by (i) at the top level,
presenting grading logic based on the WHO guideline; (ii) at
the mid-level, providing specific examples with features
leading to AI’s result for each criterion (iii) at the low level,
registering evidence into WSI to reveal more contextual
features;
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• CrossPath addresses integrability into existing workflow by
mimicking how an attending pathologist oversees trainees’
work, allowing a pathologist to shepherd mixed AI mod-
els following a top-down path to examine individual AI’s
results with evidence on-demand guided by heatmap visual-
izations.
RELATED WORK
CrossPath focuses on an interactive Computer-Aided Diagno-
sis system, which helps pathologists discover multiple histo-
logical characteristics of high-grade meningioma, with sup-
porting evidence and visualization of AI-generated results.
Correspondingly, the related work can be categorized into
three areas: (i) interactive tools for digital histology; (ii) AI
frameworks for digital histology; (iii) human-AI collaborative
platforms.
Interactive Tools for Digital Histology
Digital histology often deals with high-resolution whole slide
images. Beyond involving AI trained by domain experts, there
are a variety of tools for pathologists to define, explore, and
decide upon clinical or research usage.
When it comes to digital histology, many tools are designed
primarily for studying a localized area, as opposed to using
multiple data types to examine patients’ biopsy section at the
whole slide level. ImageJ [38] is one of the most commonly
used for scientific image analysis and has been extended by
computational medicine research. The platform provides es-
sential image processing tools to allow users to perform simple
tasks, such as nuclei segmentation. Over its 30 years of evolu-
tion, various distributions [10, 34, 37], and plugins [21] have
been increasingly integrated into the system, making it the
most widely used software in digital histology.
Besides ImageJ, others have focused on enhancing the WSI
accessibility from the perspective of non-computational users.
For example, cellprofiller [8] assists non-computational users
to perform complex morphological assays automatically with-
out writing any code quantitatively. caMicroscope [36] enables
a user to run a segmentation pipeline in a selected area and to
analyze nuclei characteristics in whole-slide images. QuPath
[4] provides extensive annotation and automation analysis
tools for pathologists, such as nuclei segmentation, positive
cell counting. Pathology Image Informatics Platform (PIIP)
[27] extends the capabilities of Sedeen viewer1 by adding plug-
ins on out-of-focus detection, region of interest transformation,
and immunohistochemical (IHC) slide analysis.
Although some systems mentioned above provide a certain
level of automation to reduce pathologists’ workload, a major-
ity of them do not support examining WSI comprehensively at
a full-slide level. As a result, such tools are hard to integrate
into pathologists’ workflow.
AI Frameworks for Digital Histology
Given the abundance of histological images, data-driven
AI can potentially be integrated into an automatic analysis
pipeline to help save medical professional’s time and effort.
1https://pathcore.com/sedeen/
Given the high resolution as well as a large amount of the
digital histology data, the mainstream frameworks incorporate
AI algorithms in Computer-Aided Diagnosis, content-based
image retrieval (CBIR), as well as discovering relationships
among various features [22]. Amongst these three primary
applications, using AI for identifying regions-of-interest for
Computer-Aided Diagnosis, e.g., identifying mitosis, is most
related to CrossPath.
Current pathology AI frameworks are majorly based on H&E
slides, focusing on detecting individual histological features.
Irshad et al. includes selected color spaces and morphological
features into mitotic cell detection pipeline to support breast
cancer grading [20]. Lu et al. use Bayesian modeling and
local-region threshold method to detect breast cancer mitotic
cells [26]. Mishra et al. propose a CNN network to identify
variable vs. necrosis osteosarcoma tumor tissues [29]. Sharma
et al. introduce a CNN network for both cancer classification
from immunohistochemistical (IHC) response and necrosis
region detection in gastric carcinoma [40]. Veta et al. propose
a nuclei segmentation pipeline with pre-processing, watershed
segmentation, and post-processing steps for breast cancer nul-
cei segmentation [44]. Zhou et al. adapt a deep-supervised
U-Net model with skipped pathways to perform nuclei seg-
mentation and enhance the performance in comparison to
traditional U-Net[49]. Yap et al. use RankBoost-permutations
to integrate multiple base classifiers to detect prominent nu-
cleoli patterns in prostate cancer, breast cancer, and renal cell
papillary cancer [48].
Several AI frameworks are also proposed based solely on Ki-
67 immunohistochemistical (IHC) tests. For example, Saha
et al. use CNN as a feature extractor with Gamma Mixture
Model to detect immuno-positive and negative cells for breast
cancer [35]. Xing et al. train a Fully Connected Convolutional
Network that can perform cell segmentation and identification
in a single stage [47]. Anari et al. utilize fuzzy c-means
clustering to extract positive and negative cells in Ki-67 slides
for meningioma tissues [2].
Although these histological image analysis frameworks re-
port satisfying performance on par with human beings, one
main problem is that they are majorly focused on single crite-
ria rather than integrating multiple at the same time. Hence,
the promise of implementing AI for a reduced workload is
obscured when doctors expect diagnosis to be based on a com-
prehensive list of criteria. Another limitation is that prior work
is mainly based on single data type, such as H&E images, as
input. In contrast, doctors in clinical practices usually refer to
multiple IHC examinations to perform a differential diagnosis
[14, 41]. Further, the non-transparent, non-explainable char-
acteristics of the end-to-end AI algorithms would limit their
applications in high-stake medical decision processes, such as
tumor grading.
Human-AI Collaborative Platforms
Although the promise of AI has enlightened the horizon of
freeing humans from tedious tasks, applying it into high-stake
applications, such as medical decision processes, is a challeng-
ing task. Thus it is important to enable human-AI collaboration
in various domains including medicine.
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In a broader context, recent research in HCI has demonstrated
a plethora of examples of human-AI collaboration. For ex-
ample, FortÃl’ enables a user to modify optimization’s result,
which serves as input for the next iteration to reflect the user’s
intent [9]. Willett et al. propose a mixed-initiative tool to
enable novice users to convert a still picture to animation by
providing a few user drawn scribbles as input, saving users’
time and effort [46]. Lee et al. implement a simulation plat-
form that accepts high-level design commands and generates
corresponding virtual mannequins in real-time [23].
Research also has shown that human-AI collaboration can
enhance tasks in the medical domain. For example, Cai et
al. propose a CBIR system where doctors can query similar
histological images with a user-adjusted refine-by-concept
tool to support differential diagnosis with digital histology
[6]. Further, integrating human domain knowledge into the
AI pipeline would enable humans to ‘supervise’ and enhance
AI via interactive machine learning. Apart from saving hu-
man’s effort, this could also help eliminate AI’s erroneous
predictions in high-stake medical applications. For example,
Ilastik [42] enables the user to draw strokes over images for
training segmentation models. The system can automatically
recommend the most critical features to reduce overfitting.
HistomicsML is an active learning [39] system that dynami-
cally queries the most uncertain patches from a random forest
classifier, thus allowing pathologists to refine the classification
model with fewer samples iteratively.
To sum up, the systems mentioned above succeed in reducing
human workload by computer automation. However, little
prior work has explored the collaborative relationship between
pathologists and AI or how to integrate AI into pathologists’
existing workflow. To fill this gap, our research investigates
how a pathologist would corporate with AI in a multi-criteria
medical application by enabling the physician to ‘shepherd’
AI in a top-down, evidence-based manner.
BACKGROUND OF MENINGIOMA
We focus on meningioma grading task to probe the design of
medical human-AI collaborative systems. According to WHO
guidelines, meningioma can be graded as I (benign), II (atypi-
cal), and III (malignant). Grade I meningioma are recognized
by their histological subtype and a lack of anaplastic features.
Grade II meningiomas are defined by one of the four follow-
ing criteria: (i) 4 to 19 mitotic (Figure 2a) count in 10 High
Power Fields (HPF); (ii) three out of five histological features:
hypercellularity (Figure 2b), prominent nucleoli (Figure 2c),
sheeting (Figure 2d, which only exists in meningothelial sub-
type), necrosis (Figure 2f), small cell (Figure 2g); (iii) brain
invasion (Figure 2h); (iv) clear cell or chordoid histological
subtype. Grade III meningiomas have 20 or more mitosis per
10 HPFs or have the histological appearance of carcinomas,
melanomas, or high-grade sarcomas. [3, 25].
Importantly, the clinical treatment of grade I and grade II/III is
different: the grade I lesions can be treated with either surgery
or external beam radiation, while grade II/III lesions often
need both [45]. Further, a study shows that grade II/III patients
experience worse prognosis even after critical treatments [31].
a
Histological features of meningiomas that CrossPath is able to process: 
(A) mitotic cell (marked in the red box); (B) hypercelluarity (abnormal 
excess of cells marked in the red box)); (C) prominent nucleoli (enlarged 
nucleoli marked in the red box); (D) meningothelial subtype (sheeting 
can only presence in this subtype); (E) fibrous subtype; (F) necrosis 
(irreversible injury to cells marked in the red box); (G) small cell (tumor 
cells with high nuclear/cytoplasmic ratio); (H) brain invasion; (I) Ki-67-
stained tissues (the positive cells have brown appearance while the 
negative ones are blue)
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Figure 2. Histological features of meningiomas that CrossPath is able
to process: (a) mitotic cell (marked in the red box); (b) hypercelluarity
(abnormal excess of cells marked in the red box)); (c) prominent nucle-
oli (enlarged nucleoli marked in the red box); (d) meningothelial sub-
type (sheeting can only presence in this subtype); (e) fibrous subtype; (f)
necrosis (irreversible injury to cells marked in the red box); (g) sugges-
tive of small cells (tumor cells with high nuclear/cytoplasmic ratio); (h)
suggestive of brain invasion (invasive tumor cells in brain tissue); (i) Ki-
67 proliferation index (the positive cells appear brown by chromogenic
immunohistochemistry).
Given the treatment and prognosis difference amongst differ-
ent tumor grades, it is crucial to support meningioma grading.
The first and foremost way to examine meningiomas is by
examining tissue slides with H&E staining. In addition, Ki-67
staining (Figure 2i) is often used as an additional reference
since the Ki-67 proliferation index is related to mitosis and
is reported as positively correlated to meningioma grading
[1]. Such multiple criteria help pathologists examine com-
prehensively on meningioma grading; an erroneous grading
comes with a high cost: either an overestimated case would
incur unnecessary treatment on patients, or an overlooked case
would result in a delay of necessary treatment.
FORMATIVE STUDY
Tizhoosh et al. summarized ten challenges in AI-aided digi-
tal histology at a high-level [43]. The paper mentioned that
diagnostic tasks are ‘non-boolean’ and diagnosis cannot be
over-simplified into a ‘yes’ or ‘no’, as machine learning tasks
usually do. Tizhoosh et al. also point out that the current
uni-tasked, weak AI cannot perfectly achieve complex, multi-
criteria tasks. Finally, a lack of transparency and interpretabil-
ity make data-driven black-box algorithms hard to understand
and hence result in an untrustworthy diagnosis. To further
understand where and how those pitfalls might occur in AI-
aided pathology, we conducted a formative study with four
pathologists in a local medical center.
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We started by describing the motivation and mission of the
project. We then asked pathologists to describe their typi-
cal process of examining a patient’s case. Next, we asked
what were the major challenges in existing pathology prac-
tice, and further inquired about their expectations on AI-aided
automatic diagnostic systems.
Existing Challenges for Pathologists
We found that there are two major challenges in current pathol-
ogy practice in the grading of meningioma.
Time consumption For grading of meningioma, the sparse
characteristics and narrow view of high power magnification
result in the time-consuming process of examining the slides
for the pathologists. A biopsy section from a patient brain
tissue would generate eight to twelve H&E slides. Patholo-
gists need to look through all those slides and integrate the
information found on each slide. Specifically, pathologists
need to follow the sampling guideline and search for histo-
logical features in the high power field. While the grading of
meningioma is a relatively easy task for experienced pathol-
ogists, for the majority of others, the grading is extremely
time-consuming and tedious, taking up to one or several hours
to go through a single patient’s case.
Subjectivity We found three factors that contribute to subjec-
tivity: (i) subjectivity due to a lack of precise definitions: the
WHO guidelines do not always provide a quantified descrip-
tion for the five histological features for high-grade menin-
gioma. For example, the ‘prominent nucleoli’ criteria requires
pathologists to report prominent nucleolus clusters. However,
the WHO guideline does not specify how large the nucleolus
should be to make them recognized as ‘prominent’. Hence,
pathologists often rely on their own experience to decide;
(ii) subjectivity in implementing the examination process. For
example, the mitotic count for grade II meningioma is de-
fined as >4 mitotic cells in 10 HPFs. However, the guideline
does not specify the sampling rules of finding those 10 HPFs.
As a result, different pathologists are likely to sample differ-
ent areas on the slide; (iii) subjectivity due to the personal
factors, such as the level of experience, time constraint, and
fatigue [11]. The subjectivity in the current pathology work-
flow would result in inter-observer variance in diagnosis, and
this would be fatal given the high stakes in medical diagnosis.
System Requirements for AI-Aided Examination
Based on the challenges mentioned above, we identify the
following system requirements based on further discussions
with pathologists.
Comprehensiveness The time consumption in current prac-
tices is in part due to the need of examining multiple criteria,
especially to justify high-grade meningioma, e.g., hypercellu-
larity, necrosis, small cell, prominent nucleoli, and sheeting.
To reduce workload and time spent for examination, the sys-
tem should similarly provide support on all these different
criteria based on multiple types and sources of data.
Explainability One important way to overcome subjectivity
is making the grading process transparent. The system should
show visual summarization of AI’s automated process and rec-
ommend to pathologists highly-suspicious regions-of-interest
for non-quantified features in WHO guidelines. Another im-
portant approach is to provide evidence-based justification—
evidence for each criterion found by AI that can be cross-
checked by pathologists.
Integrability Given its existing limitations, the system should
enable pathologists to collaborate with AI to conclude a grad-
ing diagnosis. Specifically, one suggested way of integration
is to ‘shepherd’ AI at the high level—by examining human-
readable intermediate results, and validate, cross-check with
peers, or override AI’s findings. Such a shepherding relation-
ship is similar to how currently attending pathologists delegate
work to and oversee their trainees.
DESIGN & IMPLEMENTATION
Corresponding to the meningioma grading criteria suggested
by WHO [25], we first worked with pathologists and con-
structed five meningioma datasets for training. Then we train
mixed AI models (detailed below) to examine a total of eight
criteria. We developed a front-end interface to integrate the
evidence found by AI into the H&E and Ki-67 slides, which
we describe in this section.
Comprehensive Examinations of Multiple WHO Criteria
To achieve comprehensiveness, we followed the WHO menin-
gioma grading guideline and automates eight criteria for
meningioma grading, i.e., mitotic count, Ki-67 index, hyper-
cellularity, necrosis, small cell, prominent nucleoli, sheeting,
and brain invasion. We constructed five datasets with patholo-
gists for model training. Specifically, we constructed a mitotic
nuclei dataset for mitotic cell detection, a nuclei segmentation
dataset for hypercellularity detection, a necrosis dataset for
necrosis detection, a prominent nucleoli dataset for promi-
nent nucleoli detection, and a meningioma subtype dataset
(meningothelial, fibrous, other) for sheeting pattern recogni-
tion.
In order to train the models, we first split the five datasets into
training and validation subsets. Then, we trained a mitotic
nuclei identification model, a nuclei segmentation model (for
hypercellularity), a necrosis identification model, a prominent
nucleoli identification model, and a sheeting identification
model with the corresponding training sets. For the Ki-67
index, we used positive cell count function from [15] to detect
both Ki-67 positive and negative nucleus. Due to a lack of
annotated data, we selected the top-10 512× 512× 3-pixel
patches that have the highest nuclei count within each slide
as small cell recommendations. Finally, we used a rule-based
method to differentiate the tumor and non-tumor areas for
brain invasion criterion. Please refer to Appendix A for imple-
mentation details.
To better organize AI results on the eight criteria, we worked
with pathologists to obtain their examination priority. Given
the current limitations of AI, CrossPath splits all eight criteria
into two categories based on WHO guidelines: determinis-
tic and suggestive. For the highly-prioritized criteria with
quantized values, i.e., mitotic count, Ki-67 index, CrossPath
demonstrates deterministic values directly (Figure 3b). For the
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rest of the criteria (that come with present/not present), Cross-
Path provides recommendations to pathologists. Specifically,
CrossPath calculates regions-of-interest (ROIs) that present
the probable local regions in four histological criteria (i.e., hy-
percellularity, necrosis, small cell, prominent nucleoli). Each
criterion follows different ROI sampling rules, and the areas
of each ROI might vary from one to another. For example, a
hypercellularity ROI is defined as a cluster that has more than
2000 nuclus/1HPF (Figure 4e). Please refer to Appendix B
for details on other criteria’s sampling rules. Figure 4 (e, f, g,
h) highlights the ROI samples. With the aid of ROI samples,
pathologists can prioritize their examination on an area of in-
terest with respect to a specific criterion without exhaustively
scanning the WSI looking for a starting point.
Explanation by Example Using Sampled Evidence
Crosspath provides a top-down, three levels of explanations
to illustrate a high-level line of reasoning without missing
connections to localized areas.
High-Level Logic
At the high-level, CrossPath provides two visual cues to ex-
plain the how the system follows the WHO guidelines: first,
CrossPath displays an arrow that highlights the main contribut-
ing criterion. As shown in Figure 3b, the arrow indicates that
the current suggested ‘WHO grade II’ result (Figure 3a) is gen-
erated based on the mitotic count criterion. Second, CrossPath
uses different color bars to distinguish the aforementioned de-
terministic vs. suggestive criteria. Specifically, deterministic
criteria have red or green color bars where red is for findings
that indicate higher grade (Figure 3c); the suggestive crite-
ria display orange bars. For the orange suggestive criteria,
pathologists can drill down to examine mid-level samples. If
a pathologist sufficiently overrides AI’s results, the sugges-
tive criteria will be changed to deterministic and the color bar
would be updated correspondingly. The gray bar indicates that
the corresponding criterion is not available in this case.
Mid-Level Explanation-by-Example Sampling
To better help pathologists focus on localized regions and
increase intra-observer consistency, CrossPath samples and
demonstrates evidence found by AI. For example, for the most
important mitosis criterion, CrossPath provides the following
two ‘shortcuts’ for pathologists to look into evidence of AI’s
results.
Highest Focal Region Sampling From our formative study,
we found that the high-grade meningiomas share a common
feature of increased mitosis in a localized area. Hence, Cross-
Path provides the highest focal sampling tool to help patholo-
gists better localize highly concentrated mitosis/Ki-67 index
areas. In CrossPath, the highest focal region is calculated as
the 1HPF that has the most mitosis (Figure 4a) or highest Ki-
67 index (Figure 4b). With the aid of the highest focal region
sampling tool, pathologists can verify AI’s conclusion of a
worst-case count of mitotic activity.
Highest Region Sampling One criterion of the WHO menin-
gioma grading guideline is “mitotic count in 10 consecu-
tive HPFs”. In our formative study, we found that the inter-
observer consistency of “10 consecutive HPFs” is low. In order
a b
c
Figure 3. High-level logic of CrossPath: (a) the overall suggested grad-
ing generated automatically; (b) a structured overview of each WHO
criterion, the arrow highlights the main contributing criterion to the sug-
gested grading. For each criterion, the red bar stands for the criterion
has a deterministic value while orange ones still need manual examina-
tion. The gray bar indicates the criterion is not available in this case;
(c) users can override the orange criteria by right-clicking on each item,
and change to ‘found’, ‘not found’ or ‘uncertain’. The overridden crite-
rion becomes deterministic after manual verification, and the suggested
result is updated accordingly.
to improve inter-observer consistency, CrossPath provides the
highest region sampling tool, where the highest region is de-
fined as a 2×5HPF area that contains most mitotic nucleus
(Figure 4c) or the highest Ki-67 index (Figure 4d). The highest
region sampling tool speeds up a pathologist’s work by helping
them locate an area of interest that consist of 10 consecutive
HPFs, where they can then see evidence of AI’s examination
on these 10 HPFs.
Low-Level Registration
CrossPath supports registering each piece of the mid-level
evidence into WSI to enable pathologists examine in even
higher magnification. For example, as shown in Figure 5,
pathologists can select the AI-generated prominent nucleoli
ROI (a) as CrossPath registers the corresponding evidence
into the original WSI (b), and pathologists can examine the
evidence in high magnification for low-level details (c).
Shepherding AI to Integrate into How Pathologists Work
Building off of the explainable design, Crosspath establishes
a shepherding workflow based on how attending physicians
oversee trainees’ work.
A top-down shepherding workflow As shown in Figure 6,
pathologists’ shepherding workflow with CrossPath is top-
down, and it starts from the top-level suggested result (Figure
6a). Then, pathologists continue to examine the main con-
tributing criterion (Figure 6b), and further the evidence for
the criterion (Figure 6c). Next, pathologists shepherd AI by
drilling down and tracing back to the original area on the WSI
(Figure 6d,e). With CrossPath, pathologists can make justifi-
cations on each evidence by clicking on the approve/decline
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Figure 4. Selected pieces of sampled evidence from in-the-wild detection where we applied trained models directly on multiple H&E and Ki-67 slides:
(a) a highest focal region sampling result of mitotic count on H&E slide (red box, 1HPF), the small blue frames are the 512× 512× 3-pixel evidence
patches (that are shown on the evidence list); (b) a highest focal region sampling result on Ki-67 slide (red box, 1HPF); (c) a highest region sampling
result of mitotic count on H&E slide (red box, 10HPF), the small blue frames are the 512×512×3-pixel evidence patches; (d) highest region sampling
result on Ki-67 slide (red box, 10HPF); (e) a hypercellularity ROI sample; (f) a necrosis ROI sample; (g) a small cell ROI sample; (h) a prominent
nucleoli ROI sample.
a
b
c
Figure 5. CrossPath supports registering each piece of the mid-level ev-
idence (a) into WSI (b) to enable pathologists to examine in high mag-
nification (c). The numbers in the box indicate the average prominent
nuclei density.
buttons (Figure 6f). For other criteria (Figure 6g), pathologists
can repeat the evidence examination workflow (Figure 6 (c-
f)) until they have gained sufficient confidence for a grading
diagnosis.
Heatmap visualization CrossPath shows a mitotic heatmap
(Figure 7a) with mitotic count density, a Ki-67 heatmap (Fig-
ure 7b) with Ki-67 index value, a nuclei heatmap (Figure 7c)
with nuclei density, a necrosis probability heatmap (Figure 7d)
with necrosis probability, a prominent nucleoli heatmap (Fig-
ure 7e) with prominent nucleoli density, a sheeting heatmap
(Figure 7f) that shows meningothelial vs. fibrous subtype, and
a brain invasion heatmap (Figure 7g) with tumor vs. non-tumor
regions. If the mid-level evidence samples are insufficient for
them to verify AI’s results, pathologists can go beyond the sam-
pled areas and navigate the high-heat areas using the heatmap.
Importantly, the heatmap would be used as a ‘screening tool’
to help pathologists rapidly narrow down to a localized region
for more evidence without having to scan the entire WSI.
Modifying AI results Given the non-perfect behavior of the
AI, pathologists can further shepherd AI by clicking on the
a
b
c
d
e
f
g
Figure 6. A typical workflow in CrossPath. Users first start from the
final result (a), then examine the main contributing criteria (b). They
can further examine the evidence list (c), and register back into the
original WSI in high magnification (d,e). Furthermore, users can ap-
prove/decline the evidence (f) and repeat (c-f) until they feel they have
gained sufficient confidence for a grading diagnosis for the rest of the
criteria (g).
approve/decline buttons (Figure 6f) after they have examined
the evidence within the WSI context. For the five histological
patterns as well as brain invasion criteria, pathologists can
directly override the AI-recommended results by right-clicking
on each criterion (Figure 3c). Correspondingly, the overall
suggested grading will be updated if the manually-overriden
grading indicates a different result based on WHO guidelines.
TECHNICAL EVALUATION
CrossPath uses eight models to detect various histological pat-
terns that are helpful for pathologists to reach a diagnosis. In
this section, we report the performance of AI with the valida-
tion dataset. Specifically, we validated the mitotic, necrosis,
prominent nucleoli, and sheeting criteria with a correspond-
ing validation set (mitotic count: 39 positive, 80 negative;
necrosis: 52 positive, 519 negative; prominent nucleoli: 19
positive, 57 negative; sheeting: 91 meningothelial, 70 fibrous,
101 other) and report ROC curve (Figure 8) and AUC (area
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Figure 7. Selected heatmaps from in-the-wild detection where we applied trained models directly on multiple H&E and Ki-67 slides, showing (a) mitotic
count density; (b) Ki-67 index values; (c) nuclei density; (d) necrosis probability; (e) prominent nucleoli density; (f) meningothelial vs. fibrous subtype;
(g) tumor vs. non-tumor tissues.
under curve) score of each model. Because the tasks are ma-
jorly cell-counting in hypercellularity and Ki-67 index criteria,
we validated their performance with 20 randomly-selected
512×512×3 patches and report the average error rate.
a b
c d
Figure 8. Classification performance for (a) mitotic detection, (b) necro-
sis detection, (c) prominent nucleoli detection, (d) sheeting detection
(other/meningothelial/fibrous detection). The solid lines in each sub-
figure illustrates the ROC curves of each model. The red dashed-lines
represent random-guess performance. The legend in each sub-figure re-
ports the identification AUC of each class of the corresponding model.
In summary, as shown in figure 8, CrossPath achieved AUC
of 0.842, 0.989, 0.923, and 0.834/0.673 in identifying mi-
totic nucleus, necrosis, prominent nucleolus, and meningothe-
lial/fibrous tissues separately. The average error rate of nu-
clei counting (hypercellularity) and Ki-67 index is 12.3% and
13.7%, respectively.
Due to a lack of data at present, for brain invasion and small
cell patterns, rather than drawing a conclusion, CrossPath uses
a rule-based, unsupervised approach to recommend areas for
pathologists to examine and we discuss the performance on
these two criteria later by referring to how pathologists in our
study made use of the recommendation.
WORK SESSIONS WITH PATHOLOGISTS
We conducted work sessions with pathologists using Cross-
Path. The main research questions are:
• RQ1: How do pathologists interact with CrossPath?
How do they process AI-generated results across multi-
ple criteria? How do they navigate the top-down structure
to view AI’s results and evidences that support such results?
• RQ2: Does CrossPath reduce pathologists’ effort com-
pared to their existing workflow? How much time would
a pathologist spend on one WSI in CrossPath compared ex-
isting practice? How much cognitive effort do pathologists
perceive using CrossPath compared to manual examination?
• RQ3: Does CrossPath add value if adopted to patholo-
gists’ existing workflow? What is pathologists’ perceived
value of CrossPath: what works better than manual exami-
nation and what does not?
Participants
We recruited seven pathologists from a local medical center.
The participants had experience in pathology from one to 22
years (mean=6.3), including three attendings and four senior
residents. Three participants had a background in machine
learning, and three had experience of digital whole slide imag-
ing interfaces. Three of the participants examined meningioma
slides weekly, three of them had done within half a year, and
one of them had not practiced grading meningioma for over a
year.
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Data & Apparatus
We collected three meningioma cases (two grade II, one grade
III) from a local medical center. The ground truth grading
decision were recognized by a board of pathologists. Due to
the pathologists’ limited availability of time, we only used a
small number of slides in each case: the two grade II cases
had both one H&E and one Ki-67 slide, while the grade III
case only had one H&E slide. Due to the COVID-19 pan-
demic, all sessions were conducted online. Pathologists used
Zoom’s remote control to interact with CrossPath that ran on
an experimenter’s computer.
Task & Procedure
We first introduced the background of CrossPath and provided
a detailed walkthrough of the system for each participant using
a sample case that have one H&E and one Ki-67 slide. After
that, we ran a timed section for the pathologists to grade the
three meningioma cases that contained three H&E slides and
two Ki-67 slides in total. For each case, the time was counted
from when participants first click the WSI case until they had
reached the grading diagnosis. After participants had finished
grading all three cases, we asked participants to self-report
their estimated time consumption with the three cases using
the optical microscope. In this study, we did not compare
CrossPath with traditional digital interface because partici-
pants’ experience with such interface varied. A comparison
also would not fit into the limited time each pathologist was
available to spend in our work session. After the participants
had examined all the cases, we conducted a semi-structured
interview to elicit pathologists’ response to CrossPath’s per-
ceived effort and added-value. The average duration of each
work session was about 50 minutes.
Measures
We measured CorssPath’s usability through five-level Likert
scale on various topcis, listed as follows:
• Comprehensiveness: Participants answered the following
three questions: C1:"The multi-criterion H&E features
found by the system are useful to assist the diagnosis",
C2:"The system gives a global view of histological features",
C3:"Overall, the system is comprehensive";
• Explainability: Participants answered the following three
questions: E1:"The evidence found by the system can ex-
plain the summative histological features", E2:"The sug-
gested WHO grading generated by the system is explain-
able", E3:"Overall, the system is explainable";
• Integrability: Participants answered the question: I1:"It is
easy to integrate the AI evidence and result into the current
clinical process"
• Workload: Participants answered questions followed by
NASA Task Load Index [16] in three dimensions (W1: men-
tal demand, W2: temporal demand, and W3: effort);
• Integrity: Participant answered the question: T1:"Overall,
based on the shown case study, I believe the system’s sug-
gested diagnosis matches my justification"
• Future use: Participants answered the question: F1:"If ap-
proved by the FDA, I will continue to use the system in my
practice";
FINDINGS
In this section, we summarize the result as well as the recurring
themes found in the working sessions. We further discuss three
design implications for future AI-aided diagnostic systems.
Diagnosis Consistency & Time Consumption
With the aid of CrossPath, all participants agreed with the two
grading II cases, as suggested by CrossPath. For the grade III
case, two (P4, P6) agreed with the machine-suggested grade
III, four (P1, P2, P3, P7) agreed that the case belongs to a high-
grade meningioma (grade II/III) but need more verification
from the glass slide, and one (P5) downgraded the suggested
diagnosis to grade II by overriding a number of mitotic counts
shown in the evidence panel.
The timed session shows that each pathologist spent 5.61 min-
utes (std=1.17) on average on each slide, which is 33.4% lower
than manual examination with traditional glass slide (8.43 min-
utes). Such a time reduction should factor in that pathologists
were still learning CrossPath where the time spent on each
slide included asking for clarifications and questions. Further,
it should be noted that the time reduction was achieved despite
the latency issues caused by the remote study setup.
Qualitative User Feedback and Recurring Themes
Table 1 summarizes the metrics of user response from the
post-study. Based on our observations from the work sessions
with pathologists, we present our findings below, which are
summarized into five themes.
How pathologists use CrossPath’s multiple criteria: prior-
itizing one, referring to others on demand
We observed that if a specific criterion did not satisfy the bar
of pathologist to make a diagnosis for a higher grading, pathol-
ogists would use CrossPath to browse other criteria, looking
for evidence of a differential diagnosis, until they identify suf-
ficient evidence to support their hypothesis. P3 valued such
an availability of multiple criteria: "it’s kind of a safety net to
prevent me from under grading" (P3).
In the timed section, we observed that some pathologists
started with focusing on some specific criteria to ascertain
a probable diagnosis as quickly as possible. "Looks like there
is a brain invasion, and I agree with grade II" (P1). ". . . to
be certain, I would like to go over the glass slide for the five
histological features, but for me, it is enough for grade II"
(P2). "I didn’t look at this whole side by myself. But if I’m
using just CrossPath and I believe the mitosis looks with a
grade II" (P6).
However, some pathologists would also like to see other crite-
ria and examine the slide comprehensively— "That already is
grade II by on the mitotic count, but we would also probably
go look for these other criteria" (P3). "What I would want to
do is take a look at the rest of it to make sure I’m not missing
anything" (P4). I think I have already agreed based on the
four mitosis in the HPF for grade II, but I still want to try and
navigate the other functions (P5).
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* 1: Strongly disagree – 5: Strongly agree
Question 1 2 3 4 5 Mean
C1 - - - 3 4 4.57
C2 - - - 4 3 4.43
C3 - - - 4 3 4.43
E1 - 1 1 3 2 3.86
E2 - - 1 2 3 4.33
E3 - 1 1 3 2 3.86
I1 - - - 4 3 4.43
W1 - - - 3 4 4.57
W2 - - 1 4 2 4.14
W3 - - - 5 2 4.28
T1 - - 2 4 1 3.86
F1 - - 1 4 2 4.14
Table 1. Participant response with Likert scores. The numbers indicate
how many of the participants rated the score. Note that one participant
did not answer question E2.
Pathologists did not treat all criteria provided by CrossPath
equally. Pathologists would prioritize examining a specific
criterion, e.g., brain invasion (P1), the outcome of which would
then guide them to selectively find other criteria for making
a differential diagnosis. Such a relationship between criteria
is analogous to ‘focus + context’ in information visualization
[7]—different pathologists might focus on a few different
criteria, but the other criteria are also important to serve as
context at their disposal for supporting an existing diagnosis
or finding an alternative one.
How pathologists use CrossPath’s multiple criteria: over-
laying and cross-checking one another
Although the WHO guideline does not specify a quantified Ki-
67 cut-off for meningioma grading, we observed that partici-
pants were able to incorporate the additional Ki-67 information
with H&E using CrossPath (P2, P4, P6). More specifically,
users overlapped the high Ki-67 index regions with the mitotic
density heatmap to examine whether the AI result is accurate
at a high-level. We also noticed a pathologist (P2) could use
the Ki-67 information provided by the system to improve their
diagnosis— "It did not really look like a grade I as I started
with, ..., I think the mitosis and the higher Ki makes me think
it is not a grade I" (P2).
CrossPath’s top-down flow enables pathologists to navi-
gate between high-level AI results & low-level WSI details
Amongst the seven histologic criteria provided by CrossPath,
participants seem to all agree that automating the mitotic count
criteria would best save their time— "looking for mitosis is
hard so that program really speed up [what] we’re actually
looking at" (P6). One of the main reasons that the limits the
throughput of histological diagnosis is that criteria like mitotic
count presents very small-scaled histologic features. As a
result, pathologists have to switch to high power magnifica-
tion to examine such small features in detail. Given the high
resolution of the WSI, it is possible to ‘get lost’ in the narrow
scope of HPF, resulting in a time-consuming process to go
through the entire WSI (low throughput). With CrossPath,
pathologists found its top-down flow uses specific evidence to
bridge high-level AI results at a global overview and WSI’s
low-level details in a narrow scope. "You really have to go
to high power to search for all the mitosis. So the fact that
it (CrossPath) highlights the highest region and then you can
just quickly look through that area or those evidence boxes. I
think that’s really helpful" (P5).
CrossPath’s explainable design helps pathologists see
what AI is doing (wrong)
One way of overcoming the subjectivity is promoting trans-
parency. Given the non-perfect behavior of the AI algorithms,
providing evidence-based justification was shown to be helpful
for pathologists to utilize AI’s results— "It (CrossPath) shows
areas of interests, I think it is most helpful for us, cause if it
shows there is necrosis, and it does not show us where, then
we cannot trust it" (P1). In CrossPath, users encountered false-
positive pieces of evidence in mitotic and necrosis criteria.
The sampled evidence provided by CrossPath helped the users
to understand what patterns that the AI was trying to pick up—
"For necrosis, I think it’s looking for pink type stuff, but it’s
making the mistake of picking up on some collagen, and then
there are probably not necrosis... so even when it’s wrong
it’s explainable" (P3). We also observed that explainablility
helped pathologists understand AI’s limitations and how false-
positive cases would occur— "Even under the microscope,
a lot of apoptotic bodies can look like mitotic figures, and I
think the system was bringing up a combination of those two ...
Things like that so I can understand why the system was doing
what it was doing" (P4). "I think the computer is trying to find
the dense dark areas because that’s kind of essentially what
a mitotic figure is. But of course, that’s going to catch other
things— sometimes it’s not it could just be like an apoptotic
body" (P7).
Shepherding AI with CrossPath: pathologists are able to
but do not often confirm or override AI’s result
Given the explainable evidence provided by CrossPath, it was
easy for pathologists to recognize false-positive cases and
rapidly override them— "I’m going to downgrade this to a
WHO grade II based on the histologic features vs. the mitotic.
Because I think this thing (the AI) picked up more of the neu-
trophils rather than the mitosis" (P5). However, pathologists
did not often confirm/override AI’s results on specific piece of
evidence by clicking on the approve/decline buttons or modi-
fying AI results directly on the criteria panel. We hypothesize
that this is in part related to how pathologists generate their
clinical report: pathologists make comments on founded his-
tological features if they have found them. When they were
using CrossPath, pathologists could pull the correct piece of
evidence into their report directly; otherwise, if the patholo-
gists regard the piece of evidence as false-positive, by training
they do not need to do anything since it would not appear in
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the report. On the system level, one way to incentivize patholo-
gists’ input is to make the manually overridden evidence more
useful: the AI can pick up the new annotations and retrain
the AI model. Correspondingly, the system updates the new
evidence interactively and shows the pathologists better and
refined evidence based on their annotations.
Another tool that CrossPath provides to help pathologists shep-
herd AI is the heatmap visualization of the criteria. In our
study, the users expressed that the heatmap visualization is
helpful for them to navigate the WSI and select where to look
at when verifying AI’s result, even though it took some effort
to understand it— "I think the heat maps are helpful, but I
think it took me a little bit to understand what exactly was
trying to do" (P4). "It (the heatmap) light up wherever they
(mitosis) are" (P5). "I feel like the sheeting, I thought that was
a really cool idea that the machine could kind of show where
the tissue looks the same versus different" (P6).
DISCUSSION
We discuss three design implications based on the user feed-
back from CrossPath. These implications are not limited to
meningioma grading and are expected to generalize to other
medical applications, such as AI-aided histological image
processing, or X-ray/CT/MRI image processing with AI. We
further discuss limitations that lead to potential future work to
improve the current design and implementation of CrossPath.
Summary & Implications for Design
Focus+context design Medical diagnosis involves accumu-
lating evidence from multiple criteria—our study observed
that pathologists started with a focus on one criterion while
continue to examine others for a differential diagnosis. Thus
medical AI systems not only should make multiple criteria
available, but also should support the navigation of such crite-
ria following a ‘focus+context’ design [7]. One opportunity
is to design ‘focus+context’ visualization of multiple crite-
ria, where the major challenge is to strike a balance between
juxtaposing the focused criterion with sufficient amount of
contextual criteria without overwhelming the pathologists with
too much information. It is also possible for a system to, based
on a patient’s prior history and a preprocessing of their data,
recommend a pathologist to start with a focus of certain criteria
followed by examining some others as context.
Providing evidence for AI’s result Given the current limita-
tions of AI algorithms, AI-aided diagnostic systems should
provide evidence for physicians to verify AI’s results. Similar
to CrossPath, the system can provide multi-level explanatory
evidence. For example, CrossPath offers three levels of ex-
planations: a high-level logic based on WHO guidelines, a
mid-level explanation-by-example evidence sampling, and a
low-level registration to specific WSI features. The multi-
level evidence can be especially helpful for the diseases that
follow multiple criteria and are diagnosed with rule-based
guidelines. With multi-level evidence, the users can navigate
in a top-down manner and rapidly obtain an estimation of AI
performance as well as mistakes, which also supports gaining
trust of AI-aided diagnostic systems.
Making interactions useful The ultimate goal of medical
AI is to reduce the workload of medical professionals and
help them reach a diagnosis faster. While the fully automated
diagnosis is still far under the horizon, the current AI-aided
diagnostic interface should be human-centered and integrable
to specific domains, rather than AI-centered and abstracted
from real-world scenarios. Hence, interactive features on an in-
terface should offer medical users a clear, straight-forward and
actionable implication without much extra effort to understand
them. In CrossPath, we found pathologists tended not to use
the ‘approve/decline’ and ‘modifying AI result’ functions, as
the interaction of using such functions yield little benefits com-
pared to others (e.g., seeing more evidence of AI’s results). To
overcome such limitation, making interactions clearly useful
could be a solution: the AI can follow the physician-annotated
results and update the diagnosis and evidence accordingly,
which could serve to better incentivize physicians.
Thresholding, False Positives and False Negatives
Currently, CrossPath does not support adjusting the threshold
with the front-end directly. In our user study, a participant
is interested whether they can adapt the prediction threshold
– "Some of the (mitosis) is hard to be certain, each patholo-
gist has his own threshold" (P2). Furthermore, dealing with
false positives and false negatives is another issue with a fixed-
threshold scheme as the system is. From our study, we found
out that that doctors would prefer high-sensitive results that in-
clude some false positives rather than low-sensitive results that
have false-negatives – "I guess it’s better to do false positives
and false negatives because we can always do the double-
check like being more sensitive like that" (P5). Therefore, in
future work, the system should enable adaptive thresholding
and allow pathologists to adjust the threshold on the front-end.
Further, the system should also provide as many ROIs as possi-
ble without fearing to show doctors false-positive results, since
doctors are fast in examining ROIs whereas missing important
features would come with a high cost.
Human-AI Collaboration: Where Can They Really Meet?
Identifying what AI is good at vs. what human is good at has
been a long-standing challenge in the HCI/AI communities.
In our user study, we found that the pathologists did not treat
all criteria equally, and they expressed that some automation
(the brain invasion, for example) is not as helpful as others.
A naÃr´ve solution would be partitioning the tasks into two
dimensions, i.e., human-preferable tasks and AI-preferable
tasks. However, the clear boundary of such a partition easily
blurs in a human-AI collaborative environment.
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APPENDIX
(A) DATASET DESCRIPTIONS AND MODEL DETAILS
Mitotic Count We first collected 1183 (478 positive,
705 negative) nucleus and cropped them into 64× 64× 3-
pixel2 patches. We then split the dataset with a 0.9/0.1
train/validation ratio. Next, we used a Keras implementation
of the ResNet50 model [17] and train with Adam optimizer,
binary cross-entropy loss, 100 epoch, and a batch size of 32.
To avoid false positive cases reflect the grading result, only
hard-positive nucleus with prediction probability > 0.7 are
counted as mitosis.
Ki-67 Index We used positive cell count function from [15]
to detect both Ki-67 positive and negative nucleus. The Ki-
67 index is calculated as positive-countpositive-count+negative-count × 100% in
512×512×3-patch.
Hypercelluarity We first obtained 11 regions with cell segmen-
tation with ground truth. Then we used random crop technique
and constructed a training set with 1780 512×512×3-pixel
training samples. Next we trained a U-Net nuclei segmentation
network [33] with Adam optimizer, mean-Intersection-Over-
Union metric, binary cross-entropy loss, 20 epoch, and a batch
size of 8. We further used a dynamic watersheding method to
post-process the U-Net segmentation result and finally got the
nuclei counting result.
Necrosis We collected 26 necrosis regions and 37 non-
necrosis regions in total. For each region, we used a random-
crop method to obtain 512×512×3-pixel patches. Next we
constructed a training set with 2004 patches (88 positive,
1916 negative, from 51 regions) and a validation set with
571 patches (52 positive, 519 negative, from 12 regions). We
used a ResNet50 model and train with Adam optimizer, binary
cross-entropy loss, 30 epoch and a batch size of 4.
Small Cell Due to a lack of annotated data, we selected the
top 10 512×512×3-pixel patches that have the highest nuclei
count within each slide as small cell recommendations. Note
that the small cell also shares a hypercellular pattern, only
patches that have >125 nuclei/patch are counted.
Prominent Nucleoli We collected 755 (206 positive and
549 negative) nucleus and cropped them into 64× 64× 3
pixel patches. We then split the dataset with a 0.9/0.1
train/validation ratio and trained with a ResNet50 model with
the same hyperparameters as used in mitotic count identifica-
tion. To avoid false positive cases influence the result, only
2the dimension of each pixel is 0.2508µm
nucleus that have >0.9 prediction probability are counted as
positive.
Sheeting We collected 20 meningothelial regions, 12 fibrous
regions and 12 other regions from 8 slides. For each region,
we used a random-crop method to obtain 512×512×3-pixel
patches. We constructed a training set with 2219 samples (719
meningothelial, 790 fibrous, 710 other) from 34 regions and a
validation set with 262 samples (91 meningothelial, 70 fibrous,
101 other) from 10 regions. We then trained a ResNet50 model
with the same hyperparameters as the necrosis detector.
Brain Invasion Since meningioma is a high-cellular tumor,
we used Otsu’s thresholding method [30] to differentiate the
tumor and non-tumor brain tissues with cell-counting: only
the patches that have more than 55 nucleus/512×512-pixel
patch are counted as tumor patch.
Specific thresholds used for each criterion was obtained via
discussion with a pathologist. We trained the models with the
datasets on a CentOS 7 server, with Intel Xeon W-2133 CPU,
104 GB memory, and two Nvidia RTX-2070 graphics cards.
(B) ROI SAMPLING RULES
Below are the ROI sampling rules used in CrossPath:
• a hypercellularity ROI is defined as a cluster that has
more than 2000 nuclus/1HPF;
• a necrosis ROI is defined as a cluster that has probability
>0.7 from necrosis detector;
• small cell ROIs are defined as top 10 512× 512-pixel
patches that have the most nuclei count over the slide;
• a prominent nucleoli ROI is defined as a cluster that has
more than 60 prominent nucleolus/1HPF;
The areas of hypercellularity, necrosis, and prominent nucleoli
ROIs are calculated by DBSCAN clustering algorithm [13].
If no matching ROI is found on one slide, CrossPath’s cor-
responding evidence list would be displayed as ‘no evidence
found’.
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